Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET

Company Participants

Ali Grande - Vice President, Chief Financial Officer and Treasurer

Patrick McEnany - Chairman and Chief Executive Officer

Jeff Del Carmen - Chief Commercial Officer

Steven Miller - Chief Operating Officer and Chief Scientific Officer

Conference Call Participants

Joe Catanzaro - Piper Sandler

Charles Duncan - Cantor Fitzgerald

Les Sulewski - Truist Securities

Scott Henry - ROTH Capital

Operator

Greeting and welcome to the Catalyst Pharmaceuticals CPRX First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Ali Grande, CFO of Catalyst Pharmaceuticals. Please go ahead ma’am.

Ali Grande

Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's first quarter 2022 financial results and corporate highlights. Leading the call today is Patrick McEnany, Chairman and Chief Executive Officer. We are also joined by Dr. Steve Miller, our Chief Operating Officer and Chief Scientific Officer; and Jeffrey Del Carmen, our Chief Commercial Officer. Further for the Q&A session, we'll have Dr. Gary Ingenito, our Chief Medical and Regulatory Officer and Brian Elsbernd, our Chief Legal and Compliance Officer.

Before we begin, I would like to remind you that in our presentation this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of the Federal Securities Laws. These statements relate to our current expectations, estimates, and projections, and are not guarantees of future performance. They involve risks, uncertainties, and assumptions that are difficult to predict and may prove not to be accurate, especially in light of the effects of COVID-19. Actual results may vary from the expectations containing our forward-looking statements. These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings, including the risk factors described in our 2021 annual report on Form 10-K.

At this time, I’ll turn the call over to Pat.

Patrick McEnany

Thanks, Ali. Good morning, everyone and thank you for joining us today for Catalyst first quarter 2022 financial results and update call. As you can see, we had a remarkable first quarter. As we delivered record net product revenue of $43 million, a 42.5% increase, compared to Q1 of 2021 and ended the quarter with $198 million in cash and short-term investments.